Evidence map›Paper›PMID 25869502›Full record

ReviewVascular pharmacology2015

Exosomes and exosomal miRNAs in cardiovascular protection and repair.

Costanza Emanueli, Andrew I U Shearn, Gianni D Angelini, Susmita Sahoo

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vascular pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 151 papers.

0numbers the graph read from it
0cells of the map it votes in
151citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

151 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Clinical Applications of Extracellular Vesicles: Promises and Pitfalls.International journal of molecular sciences · 2026
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

91 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Costanza EmanueliBristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, England, UK; National Heart and Lung Institute, Imperial College of London, London, England, UK. Electronic address: Costanza.Emanueli@bristol.ac.uk.
Andrew I U ShearnBristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, England, UK.
Gianni D AngeliniBristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, England, UK; National Heart and Lung Institute, Imperial College of London, London, England, UK.
Susmita SahooCardiovascular Research Institute, Icahn School of Medicine, Mount Sinai, NY, USA.

Funding

Therapeutic Mechanisms of Human CD34 ExosomesR01HL124187 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SAHOO, SUSMITA · 2014 to 2018
$2.1M
British Heart FoundationNHLBI NIH HHS R01 HL124187NHLBI NIH HHS R01HL124187
6 · The paper itself

Abstract

Cell-cell communication between cardiac and vascular cells and from stem and progenitor cells to differentiated cardiovascular cells is both an important and complex process, achieved through a diversity of mechanisms that have an impact on cardiovascular biology, disease and therapeutics. In recent years, evidence has accumulated suggesting that extracellular vesicles (EVs) are a new system of intercellular communication. EVs of different sizes are produced via different biogenesis pathways and have been shown to be released and taken up by most of known cell types, including heart and vascular cells, and stem and progenitor cells. This review will focus on exosomes, the smallest EVs (up to 100nm in diameter) identified so far. Cells can package cargoes consisting of selective lipids, proteins and RNA in exosomes and such cargoes can be shipped to recipient cells, inducing expressional and functional changes. This review focuses on exosomes and microRNAs in the context of cardiovascular disease and repair. We will describe exosome biogenesis and cargo formation and discuss the available information on in vitro and in vivo exosomes-based cell-to-cell communication relevant to cardiovascular science. The methods used in exosome research will be also described. Finally, we will address the promise of exosomes as clinical biomarkers and their impact as a biomedical tool in stem cell-based cardiovascular therapeutics.

Indexed as

AnimalsBiomarkersCardiovascular DiseasesCell CommunicationCell DifferentiationExosomesHumansMicroRNAsBiomarkersMicroRNAsAngiogenesisCardiac protectionExosomesIschemiaIschemia/reperfusion injurymicroRNAsStem cells

Identifiers

PMID25869502
PMCPMC4838026

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.